Vanguard Global Advisers’s C4 Therapeutics CCCC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$143K Buy
42,890
+9,058
+27% +$33.8K ﹤0.01% 2613
2026
Q2
$158K Hold
33,832
– – ﹤0.01% 2593
2026
Q1
$89K Buy
+33,832
New +$79.7K ﹤0.01% 2769

Other funds holding CCCC

Vanguard Global Advisers's CCCC Position: Q3 2026 in Review

Vanguard Global Advisers increased its C4 Therapeutics (CCCC) stake by 27% in Q3 2026, buying an estimated $33.8K and bringing the position to 42,890 shares worth $143K. The position accounts for ﹤0.01% of the portfolio, ranked #2613.

Vanguard Global Advisers first reported a position in CCCC in Q1 2026 and has held it in 3 quarters since. The position peaked at $158K in Q2 2026. 151 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.

  • Vanguard Global Advisers held 42,890 shares of C4 Therapeutics worth $143K as of Q3 2026.
  • Vanguard Global Advisers bought 9,058 C4 Therapeutics shares in Q3 2026, an estimated $33.8K.
  • C4 Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #2613 holding.
  • Vanguard Global Advisers first reported a position in C4 Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's C4 Therapeutics position peaked at $158K in Q2 2026.
  • 151 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.